- AU$10.33m
- AU$9.81m
- AU$6.03m
- 16
- 39
- 42
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.6 | ||
| Price to Tang. Book | 4.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -101.19% | ||
| Return on Equity | -98.08% | ||
| Operating Margin | -114.55% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.3 | 4.09 | 4.72 | 5.91 | 6.03 | 10.2 | 14.3 | 46.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as motor neuron disease (MND) and amyotrophic lateral sclerosis (ALS). The Company’s products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. Its core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography (EMG) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. It is also commercializing its advancement in its technology, the NeuroStrip.
Directors
- Roger Hawke NEC
- Robert Wong CEO (53)
- Peter Shann Ford FDR
- Neale Java CFO
- Brett Crowley SEC
- William McMurray NED (58)
- Lindsay Phillips NED
- Damian Lismore NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 26th, 2005
- Public Since
- December 7th, 2020
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 251,986,927
- Address
- Suite 5.01, 697 Bourke Road, Camberwell, SYDNEY, 3124
- Web
- https://www.controlbionics.com/
- Phone
- +61 398973576
- Contact
- Brett Crowley
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for CBL
Control Bionics Ltd Annual Shareholders Meeting
Similar to CBL
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
What is the Control Bionics share price?
As of Today at 20:03 UTC, shares in Control Bionics are trading at AU$0.04. This share price information is delayed by 15 minutes.
How has the Control Bionics share price performed this year?
Shares in Control Bionics last closed at AU$0.04 and the price had moved by +2.5% over the past 365 days. In terms of relative price strength the Control Bionics share price has outperformed the ASX All Ordinaries Index by +0.97% over the past year.
What are the analyst and broker recommendations for Control Bionics?
The overall consensus recommendation for Control Bionics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Control Bionics dividend yield?
Control Bionics does not currently pay a dividend.
Does Control Bionics pay a dividend?
Control Bionics does not currently pay a dividend.
When does Control Bionics next pay dividends?
Control Bionics does not currently pay a dividend.
How do I buy Control Bionics shares?
To buy shares in Control Bionics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Control Bionics?
As of the previous close price of AU$0.04, shares in Control Bionics had a market capitalisation of AU$10.33m.
Where are Control Bionics shares listed?
Here are the trading details for Control Bionics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CBL
What kind of share is Control Bionics?
Based on an overall assessment of its quality, value and momentum Control Bionics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Control Bionics share price forecast for 2025?
The analyst consensus target price for shares in Control Bionics is AU$0.06. That is 46.34% above the last closing price of AU$0.04.
Analysts covering Control Bionics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
Find out moreWhat is the trend in the Control Bionics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Control Bionics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -37.21%.
As of the last closing price of AU$0.04, shares in Control Bionics were trading -31.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Control Bionics PE Ratio?
The Control Bionics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Control Bionics?
Control Bionics' management team is headed by:
- Roger Hawke - NEC
- Robert Wong - CEO
- Peter Shann Ford - FDR
- Neale Java - CFO
- Brett Crowley - SEC
- William McMurray - NED
- Lindsay Phillips - NED
- Damian Lismore - NID